Effects of fluoroquinolones on experimental pneumonia caused by penicillin-resistantStreptococcus pneumoniae in mice
- 13 Downloads
The in vitro and in vivo activities of several fluoroquinolones, ampicillin and cefteram-pivoxil were investigated against penicillin-resistantStreptococcus pneumoniae (PRSP). The MIC90s of sparfloxacin, levofloxacin, tosufloxacin, AM-1155, ampicillin, and cefteram-pivoxil for 13 PRSP strains were 0.78, 3.13, 0.39, 1.56, 3.13, and 3.13 μg/mL, respectively. An experimental fatal pneumonia was induced by intranasal inoculation of PRSP No. 65 in CBA/J mice. The fluoroquinolones were effective against the experimental pneumonia, but ampicillin and cefteram-pivoxil were not sufficiently effective. The oral 50% effective doses (ED50) of sparfloxacin, levofloxacin, tosufloxacin, and AM-1155 on the experimental pneumonia were 6.09, 49.3, 5.07, and 8.59 mg/kg/dose, respectively, when treatment was initiated 3 hours after infection and were 30.0, >50, 17.7, and 45.9 mg/kg/dose, respectively, when treatment was initiated 24 hours after infection. These results suggest that some fluoroquinolones such as sparfloxacin, tosufloxacin and AM-1155 may be effective in the treatment of pneumonia due to PRSP in humans.
Key Wordsfluoroquinolones pneumonia mouse model Streptococcus pneumoniae penicillin resistance
Unable to display preview. Download preview PDF.
- 1.Arthur LB, Steven DB, William JN. In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin againstStreptococcus pneumoniae isolates. Antimicrob Agents Chemother 1995;39:2193–2196.Google Scholar
- 3.Kan KM, Luey KY, Fung SM, Yiu PP, Harden TJ, Cheung MM. Emergence of multiple-antibiotic-resistantStreptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1995;39:2667–2670.Google Scholar
- 6.Konno M. An epidemiological study of penicillin-resistantStreptococcus pneumoniae in Japan. J Jap Assoc Infect Dis 1994;68:1338–1351.Google Scholar
- 8.Girade AE, Girard D, Gootz TD, Faiella JA, Cimochowski CR. In vitro efficacy of trovafloxacin (CP-99219), a new quinolone with extended activities against gram-positive pathogens,Streptococcus pneumoniae, andBacteroides fragilis. Antimicrob Agents Chemother 1995;39:2210–2216.Google Scholar
- 13.Azoulay-Dupuis E, Vallee E, Veber B, Bedos JP, Bauchet J, Pocidalo JJ. In vivo efficacy of a new fluoroquinolone, sparfloxacin against penicillin-susceptible and-resistant and multiresistant strains ofStreptococcus pneumoniae in a mouse model of pneumonia. Antimicrob Agents Chemother 1992;36:2698–2703.PubMedGoogle Scholar
- 14.Garau J, Vercken JB. Efficacy of sparfloxacin in the treatment of 312 cases of pneumococcal community acquired pneumonia: a pool data analysis. Program and abstracts of the 5th International Symposium on New Quinolones 1994. Singapore, Singapore, August 12–14, 1994 (abstr 40).Google Scholar
- 16.Takashima K, Tateda K, Matsumoto T, Ito T, Iizawa Y, Yamaguchi K. Experimental respiratory tract infection caused by penicillin-resistantStreptococcus pneumoniae in CBA/J mice. Therapeutic Res (Japan) 1995;16:43–436.Google Scholar
- 17.Tateda K, Takashima K, Miyazaki H, Ito T, Hatori T, Yamaguchi K. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacious of antibiotics in this model. Antimicrob Agents Chemother 1996;16:433–436.Google Scholar
- 18.Miller LC, Tainter ML. Estimation of the ED50 and its error by means of logarithmic-probit graph. Proc Soc Exp Biol Med 1944;57:261–264.Google Scholar